Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors

This study tests whether adding sunitinib (a targeted therapy pill) to lutetium-177 dotatate (a radioactive treatment) improves outcomes in people with pancreatic neuroendocrine tumors (a specific type of pancreatic cancer) that have spread and cannot be surgically removed. **You may be eligible if...** - You are 18 or older - You have confirmed metastatic or unresectable pancreatic neuroendocrine tumors (PNETs) - Your tumor takes up the radioactive tracer on a special scan (SSR PET/CT), meaning it is eligible for lutetium-177 dotatate treatment - Your cancer has progressed in the last 12 months - You have had no more than one prior systemic therapy (somatostatin analogs don't count) - Your blood counts, kidney, and liver function meet minimum thresholds **You may NOT be eligible if...** - Your tumor does not take up the radioactive tracer on the required scan - You are pregnant or breastfeeding - Your kidney or liver function is significantly impaired - You have had more than one prior line of non-somatostatin systemic therapy Talk to your doctor to see if this trial is right for you.